Abstract | PURPOSE: METHODS: Three patients with persistent or recurrent GTD cared for at the Cleveland Clinic received a high-dose chemotherapy program (with stem cell support), one as management for etoposide-associated acute leukemia resulting from her "standard dose" treatment program. RESULTS: While the indications for use of a dose-intensive strategy, and the ultimate clinical course, differed in the three patients, collectively these cases raise relevant questions regarding optimal management of high risk and recurrent GTD. CONCLUSION: The experience represented in this report support the earlier use of cisplatin-based chemotherapy in the management of high-risk and recurrent GTD, and the possible administration of a high-dose chemotherapy program in the rare patient who recurs following "standard dose" platinum-based treatment.
|
Authors | Maurie Markman |
Journal | Journal of cancer research and clinical oncology
(J Cancer Res Clin Oncol)
Vol. 130
Issue 7
Pg. 383-7
(Jul 2004)
ISSN: 0171-5216 [Print] Germany |
PMID | 15150657
(Publication Type: Case Reports, Journal Article, Review)
|
Chemical References |
- Antineoplastic Agents, Phytogenic
- Etoposide
|
Topics |
- Adult
- Antineoplastic Agents, Phytogenic
(administration & dosage, adverse effects)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Drug Administration Schedule
- Etoposide
(administration & dosage, adverse effects)
- Female
- Gestational Trophoblastic Disease
(drug therapy)
- Humans
- Leukemia
(chemically induced, drug therapy)
- Pregnancy
- Uterine Neoplasms
(drug therapy)
|